What is the 13F Pro Quality Score for JANX?

13F Pro ranks Janux Therapeutics, Inc. (JANX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View JANX's current score at https://13fpro.ai/research/JANX (free sign-up required for the full ranking).

Which hedge funds own the most JANX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of JANX include RA CAPITAL MANAGEMENT, L.P., BlackRock,, JANUS HENDERSON GROUP PLC. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/JANX as soon as new 13F filings post.

Where does 13F Pro source JANX data?

All Janux Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Janux Therapeutics, Inc. files with the SEC under CIK 1817713. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is JANX in?

Janux Therapeutics, Inc. (JANX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is JANX research updated on 13F Pro?

JANX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Janux Therapeutics, Inc.(JANX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1817713 JANX stock profile & AI dashboard →

13F Pro Quality Score

24.8/100

Rank #2,573 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

90.8/100

Profitability

2.8/100

Balance Sheet

16.9/100

Earnings Quality

30.0/100

Free Cash Flow

3.2/100

Institutional Flow

17.0/100

Revenue Scale

4.2/100

Dilution Risk

1.2/100

JANX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Janux Therapeutics, Inc. (JANX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores JANX at 24.8/100 on a 32-signal composite quality model, placing it at rank #2,573 of 2,879 stocks — the bottom half of the AI-ranked universe. JANX scores in the top quartile across revenue growth (90.8). Areas of concern include profitability (2.8) and free cash flow (3.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Janux Therapeutics, Inc. reports quarterly revenue of $3.7M, net income of $-24.4M, free cash flow of $-12.6M. Top institutional holders of JANX by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., BlackRock,, JANUS HENDERSON GROUP PLC, based on the most recent SEC filings. JANX trades on the Nasdaq exchange and files with the SEC under CIK 1817713. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate JANX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Janux Therapeutics, Inc. directly from SEC EDGAR. Janux Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 8 and 76 since 2023, currently 24.8 — an improving long-term trajectory across 40 quarterly and live scoring snapshots.

✦

Fun facts about Janux Therapeutics, Inc.

Quirks, history, and lore behind JANX — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Southern California · focused on oncology.
2
The Numbers
Like most clinical-stage biotechs, it generates no product revenue and burns through cash funding trials — market cap has swung dramatically on trial readouts.
3
The History
Founded in the 2010s, it was built around a proprietary platform designed to engineer T-cell engager therapies — a hot area of cancer immunology research.
4
The Secret
Its core technology is a TRACTr platform that aims to create tumor-targeted T-cell engagers with controllable, conditional activation — trying to make the therapy smarter and safer.
5
The Lore
The company's name is a nod to Janus, the two-faced Roman god — fitting for a bispecific antibody platform designed to bridge two targets at once.
6
The Giveaway
Its lead program JANX007 targets PSMA in prostate cancer — and its ticker, conveniently, sounds like it belongs to a Roman deity running a La Jolla biotech.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$3.7M

Net Income

Q1 2026

$-24.4M

Free Cash Flow

Q1 2026

$-12.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-5.6% YoY

$10.0MFY 2025

FY20 $0.00FY21 $3.6MFY24 $10.6MFY25 $10.0M

Net Income

-64.7% YoY

$-113.6MFY 2025

FY20 $-6.8MFY21 $-32.7MFY24 $-69.0MFY25 $-113.6M

Operating Income

-59.5% YoY

$-157.7MFY 2025

FY20 $-4.8MFY21 $-32.9MFY24 $-98.8MFY25 $-157.7M

EPS (Diluted)

-43.0% YoY

$-1.83FY 2025

FY20 —FY21 $-1.09FY24 $-1.28FY25 $-1.83

Total Assets

-5.6% YoY

$1.00BFY 2025

FY20 $16.2MFY21 $379.8MFY24 $1.06BFY25 $1.00B

Op. Cash Flow

-87.7% YoY

$-82.2MFY 2025

FY20 $-4.4MFY21 $-17.0MFY24 $-43.8MFY25 $-82.2M

Metric	FY 2025	FY 2024	FY 2021	FY 2020	FY 2019
Revenue	$10.0M -5.6%	$10.6M +191.1%	$3.6M	$0.00	—
Net Income	$-113.6M -64.7%	$-69.0M -111.2%	$-32.7M -381.6%	$-6.8M	—
Operating Income	$-157.7M -59.5%	$-98.8M -200.2%	$-32.9M -579.9%	$-4.8M	—
EPS (Diluted)	$-1.83 -43.0%	$-1.28 -18.0%	$-1.09	—	—
Total Assets	$1.00B -5.6%	$1.06B +179.5%	$379.8M +2242.1%	$16.2M	—
Operating Cash Flow	$-82.2M -87.7%	$-43.8M -158.1%	$-17.0M -288.6%	$-4.4M	—

AI Insight: JANX Financial Trends

Janux burns through $66M in equity over the past year despite sporadic revenue recognition, with operating losses consistently above $30M per quarter.

• Equity declined from $1,023M in Q4 2024 to $942M in Q1 2026, representing $81M in shareholder value erosion.

• Operating losses remained elevated, ranging from $29M to $45M per quarter throughout the eight-quarter period.

• Revenue recognition remains lumpy and minimal, totaling only $23M across eight quarters with five quarters showing zero revenue.

⚠ Operating cash flow burn accelerated to $29M in Q4 2025 from $13M in Q3 2025, signaling intensifying cash consumption.

⚠ Company maintains debt-free balance sheet with substantial equity cushion, providing runway for continued operations despite losses.

AI Insight: JANX Ratio Trends

Janux shows persistent negative returns across all profitability metrics with ROIC deteriorating from -8.4% in Q2 2024 to -14.5% in Q1 2026.

• ROIC declined from -8.4% in Q2 2024 to -14.5% in Q1 2026, reflecting worsening capital efficiency.

• ROE deteriorated from -3.6% in Q2 2024 to -10.3% in Q1 2026, showing declining shareholder returns.

• All profitability metrics remain deeply negative throughout the observation period with no clear improvement trend.

⚠ Volatile quarterly ROIC swings between -11.3% and -21.9% suggest unstable operational performance.

⚠ Missing operating margin and net profit margin data limits visibility into core operational trends.

Get alerted when JANX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Janux Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of JANX

RA CAPITAL MANAGEMENT, L.P.
$155.5M11,189,693 sh
BlackRock, Inc.
$75.5M5,433,233 sh
JANUS HENDERSON GROUP PLC
$58.3M4,196,409 sh
Prosight Management, LP
$49.3M3,550,000 sh
FMR LLC
$35.2M2,535,724 sh
STATE STREET CORP
$34.2M2,464,017 sh
VANGUARD CAPITAL MANAGEMENT LLC
$25.2M1,811,365 sh
TCG Crossover Management, LLC
$24.9M1,789,617 sh
Alyeska Investment Group, L.P.
$22.3M1,601,089 sh
WELLINGTON MANAGEMENT GROUP LLP
$22.2M1,597,650 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$155.5M	11,189,693
BlackRock, Inc.	$75.5M	5,433,233
JANUS HENDERSON GROUP PLC	$58.3M	4,196,409
Prosight Management, LP	$49.3M	3,550,000
FMR LLC	$35.2M	2,535,724
STATE STREET CORP	$34.2M	2,464,017
VANGUARD CAPITAL MANAGEMENT LLC	$25.2M	1,811,365
TCG Crossover Management, LLC	$24.9M	1,789,617
Alyeska Investment Group, L.P.	$22.3M	1,601,089
WELLINGTON MANAGEMENT GROUP LLP	$22.2M	1,597,650

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put JANX on your watchlist

Track score changes the day Janux Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is JANX a good stock to buy?

13F Pro's AI-powered analysis of Janux Therapeutics, Inc. (JANX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for JANX are available on the JANX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own JANX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling JANX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Janux Therapeutics, Inc.'s investment landscape.